First National Bank of Mount Dora Trust Investment Services trimmed its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 68.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,603 shares of the company's stock after selling 33,470 shares during the quarter. First National Bank of Mount Dora Trust Investment Services' holdings in Merck & Co., Inc. were worth $1,401,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Tallon Kerry Patrick purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth $365,000. Brighton Jones LLC raised its position in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,350,000. Strategic Financial Concepts LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $2,990,000. Finally, Moloney Securities Asset Management LLC raised its position in Merck & Co., Inc. by 1.6% during the fourth quarter. Moloney Securities Asset Management LLC now owns 13,987 shares of the company's stock valued at $1,391,000 after acquiring an additional 214 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Merck & Co., Inc.
In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the company's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the sale, the senior vice president now directly owns 7,778 shares in the company, valued at $643,707.28. This represents a 35.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by company insiders.
Merck & Co., Inc. Price Performance
NYSE MRK traded down $0.14 during trading hours on Friday, hitting $81.68. 14,549,536 shares of the company's stock traded hands, compared to its average volume of 12,851,201. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63. The company has a market capitalization of $205.09 billion, a PE ratio of 12.14, a PEG ratio of 0.77 and a beta of 0.38. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm's 50-day moving average is $78.87 and its 200-day moving average is $89.44.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The company had revenue of $15.53 billion during the quarter, compared to analysts' expectations of $15.59 billion. During the same quarter in the prior year, the company earned $2.07 EPS. Merck & Co., Inc.'s revenue was down 1.6% compared to the same quarter last year. Equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 8th. Shareholders of record on Monday, June 16th will be issued a $0.81 dividend. This represents a $3.24 annualized dividend and a yield of 3.97%. The ex-dividend date is Monday, June 16th. Merck & Co., Inc.'s payout ratio is currently 47.16%.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. Guggenheim reaffirmed a "buy" rating and issued a $115.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Deutsche Bank Aktiengesellschaft cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price objective for the company from $128.00 to $105.00 in a report on Tuesday, February 18th. Wall Street Zen cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a report on Friday, April 25th. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Finally, Citigroup restated a "neutral" rating and issued a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $109.19.
Read Our Latest Analysis on Merck & Co., Inc.
About Merck & Co., Inc.
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report